Government caps trade margins on 137 cancer drugs at 30%, prices effective November 9

The government has notified a 30% cap on trade margins for 137 cancer drugs, with the new pricing structure taking effect from November 9. The measure is designed to lower the cost burden on patients purchasing these essential medicines.

The price regulation applies across the supply chain, limiting the margins that distributors and retailers can add to the base price of these medications. Cancer drugs covered under this directive include commonly prescribed treatments for various malignancies.

This intervention reflects the government's effort to balance pharmaceutical industry viability with patient affordability. By controlling intermediary markups, the policy aims to make life-saving cancer treatments more accessible to a broader patient base while ensuring the supply chain remains functional.